Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial
Introduction: The combination therapy of aliskiren and renin–angiotensin–aldosterone system (RAAS) blocker in chronic kidney disease (CKD) is controversial. Whether such dual blockade can effectively apply to patients with CKD irrespective of stage and amount of proteinuria remains uncertain. Method...
Main Authors: | Men-Tai Wu, Shi-Cheng Tung, Kao-Tai Hsu, Chien-Te Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publications
2014-09-01
|
Series: | Journal of the Renin-Angiotensin-Aldosterone System |
Online Access: | https://doi.org/10.1177/1470320312467560 |
Similar Items
-
Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria
by: Tsukasa Nakamura, et al.
Published: (2012-03-01) -
Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction
by: Chien-Ning Hsu, et al.
Published: (2015-09-01) -
Aliskiren accumulates in the kidney: does it matter?
by: David L Feldman, et al.
Published: (2008-03-01) -
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
by: Franz Schaefer, et al.
Published: (2024-03-01) -
Aliskiren and losartan trial in non-diabetic chronic kidney disease
by: Keng-Thye Woo, et al.
Published: (2014-12-01)